Search or ask a question

What is the medicinal treatment of ovarian cancer?

Maintenance therapy

Targeted therapy

Best insight from top research papers

The medicinal treatment of ovarian cancer includes a combination of cytoreductive surgery, platinum-based chemotherapy, targeted therapies, and immunotherapy . Platinum-based chemotherapy drugs such as cisplatin, carboplatin, paclitaxel, and docetaxel are commonly used in combination therapy . Targeted therapies aim to selectively target molecules and mechanisms that cause chemoresistance, such as efflux pump inhibitors, tyrosine kinase inhibitors, and PARP inhibitors like olaparib . Immunotherapy, particularly immune checkpoint inhibitors, is being investigated in combination with chemotherapy, anti-angiogenetics, PARP inhibitors, and radiotherapy . The use of poly ADP-ribose polymerase (PARP) inhibitors, bevacizumab, and drugs targeting homologous recombination deficiency is becoming more common in the treatment of ovarian cancer . Overall, a comprehensive approach involving surgery, chemotherapy, targeted therapies, and immunotherapy is necessary for the effective treatment of ovarian cancer.

Answers from top 4 papers

PDF

Open Access

More filters

Papers (4)	Insight
Open access•Journal Article•DOI Treatment of epithelial ovarian cancer Lindsay M. Kuroki, Saketh R. Guntupalli - Show less +1 more 09 Nov 2020-BMJ 255 Citations	The paper discusses the treatment of ovarian cancer, including surgical cytoreduction followed by adjuvant chemotherapy. It also mentions the use of maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and drugs targeting homologous recombination deficiency.
Book Chapter•DOI Ovarian cancer: Targeted therapies and mechanisms of resistance Deepika Sarvepalli, Mamoon Ur Rashid, Hammad Zafar, Sundas Jehanzeb, Effa Zahid, Sarfraz Ahmad - Show less +5 more 01 Jan 2021 1 Citations	The paper discusses the treatment of ovarian cancer, which includes surgical removal of the tumor mass followed by chemotherapy, hormone therapy, and/or radiotherapy.
Open access•Journal Article•DOI Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso - Show less +8 more 15 Mar 2021-Cancers 13 Citations	The medicinal treatment of ovarian cancer includes cytoreductive surgery, platinum-based chemotherapy, and targeted therapies such as PARP inhibitors and immune checkpoint inhibitors.
Patent Medicine for treating ovarian cancer and preparation method and application thereof Linlin Ma, Zhang Xiaoyu, Qi Qi, Shi Simao, Guo Ying, Sun Yuhua, Mengying Wang, Peng Limin, Lu Caixia, Meng Xiaoyu - Show less +9 more 07 Aug 2020	The medicinal treatment of ovarian cancer mentioned in the paper is a pharmaceutical composition comprising olaparib and Plasticines alkaloid compounds.

My columns

Related Questions

How does ovarian cancer afeccts lide?5 answersOvarian cancer significantly impacts life due to its high mortality rates and challenges in early diagnosis. It is the most lethal gynecological malignancy and the fifth leading cause of cancer death in women, with varying incidence rates globally. Factors contributing to ovarian cancer risk include genetic mutations like BRCA1 and BRCA2, hormonal influences, environmental exposures, and lifestyle choices. The disease's complexity is further highlighted by the presence of ovarian cancer stem cells, which play a crucial role in recurrence and progression. Immunotherapy is being actively investigated as a potential treatment approach, aiming to stimulate tumor-specific effector T cells and prevent disease progression. Overall, the impact of ovarian cancer on life underscores the importance of continuous research, early detection strategies, and advancements in treatment modalities to improve outcomes and quality of life for affected individuals.

What are the current advancements in the diagnosis and treatment of ovarian cancer?5 answersCurrent advancements in the diagnosis and treatment of ovarian cancer encompass a range of innovative approaches. Nanotechnology, particularly nanomedicine, offers novel drug carriers like liposomes and polymer nanoparticles for targeted drug delivery, enhancing efficacy while minimizing side effects. Targeted therapies, such as PARP inhibitors and anti-VEGF antibodies, have shown significant efficacy in treating ovarian cancer, with ongoing research into alternate angiogenic pathways and growth-dependent pathways. Peptides have emerged as promising tools for both diagnosis and treatment, with applications in radiolabeled peptides for diagnostics and peptide-based vaccines for immunotherapy. Recent studies have also highlighted the importance of biomarkers like CA125 decline and ctDNA testing for prognosis and disease monitoring, emphasizing the need for wider genetic testing and improved physician education on testing significance. These advancements collectively contribute to improving outcomes for ovarian cancer patients.

What is the treatment for an ovarian cyste?4 answersThe treatment for an ovarian cyst varies depending on factors like size, symptoms, and patient's age. Surgical intervention is often recommended for large cysts, especially in cases of infertility or failed pregnancies. However, small asymptomatic cysts in women over 35 may not require surgery. Traditional Chinese medicines have been developed into hot compression packs, showing efficacy in treating ovarian cysts without toxic effects. Another herbal medicine combines various roots and rhizomes to resolve blood stasis and effectively treat ovarian cysts, as proven in clinical experiments. Additionally, a medicament composed of multiple herbal ingredients has shown success in balancing Yin and Yang, detoxifying, and relieving pain associated with ovarian cysts. Overall, treatment options range from surgical procedures to herbal remedies, with individualized approaches based on the specific characteristics of the cyst and the patient.

Is there immunotherapy treatment for ovarian cancer?5 answersImmunotherapy treatment options for ovarian cancer have been explored in several studies. Immune checkpoint inhibitors (ICIs) have been approved for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. Ovarian cancer is considered an immunogenic tumor, and immunotherapies targeting components of the tumor microenvironment have been integrated into treatment options, including immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Key strategies in immunotherapy of ovarian cancer include checkpoint blockade agents, vaccines, adoptive cell transfer, and combinations of these methods. Although studies evaluating immunotherapy, particularly immune checkpoint inhibitors, have shown limited activity in ovarian cancer, some patients have benefited greatly. Further research is needed to identify new strategies and improve the use of immunotherapy in ovarian cancer treatment.

How does chemotherapy impact ovarian follicles?5 answersChemotherapy has a detrimental impact on ovarian follicles. It induces ovarian damage and follicle loss, particularly affecting primary and secondary follicles rather than primordial follicles. The number of follicles at each developmental stage, including primordial, primary, secondary, and tertiary, significantly decreases after chemotherapy. Chemotherapy agents, such as cyclophosphamide and doxorubicin, cause DNA double-strand breaks (DSBs) and apoptotic death of primordial follicle oocytes, leading to the massive loss of ovarian reserve. Additionally, chemotherapy can induce stromal-microvascular damage and hypoxia, indirectly affecting ovarian reserve. However, there is evidence suggesting that some primordial follicles may survive and remain in the ovary after chemotherapy, supporting ovarian tissue cryopreservation for fertility preservation. Various strategies, including the use of gonadotropin-releasing hormone (GnRH) antagonists, are being explored to protect granulosa cells and mitigate the gonadotoxic effects of chemotherapy.

What are the different types of surgery for ovarian cancer?5 answersSurgery for ovarian cancer includes various procedures such as opportunistic salpingectomy, peritoneal cytoreductive surgery, lymph node dissections, tumor debulking, and intestinal resection. Opportunistic salpingectomy involves the removal of the fallopian tubes during other surgeries like hysterectomy. Peritoneal cytoreductive surgery aims to reduce the tumor burden in the peritoneal cavity. Lymph node dissections are performed to determine the extent of the disease and its prognosis. Tumor debulking is a procedure that aims to achieve maximal cytoreduction, ideally with no residual disease, to enhance the effectiveness of subsequent chemotherapy. Intestinal resection may be necessary during cytoreductive surgery for ovarian cancer, particularly when there are metastases involving the bowel. Other procedures such as cholecystectomy, porta hepatis debulking, and omental bursectomy may also be performed for advanced ovarian cancer involving the upper abdomen.

See what other people are reading

The name of the paper by Cutter, Burton, and Emrich in 2003?

The paper by Cutter, Burton, and Emrich in 2003 is not explicitly mentioned in the provided contexts. However, the contexts provided discuss various inventions related to paper cutters. These inventions include a paper cutting cutter with an illuminating mechanism for precise cutting, a novel paper cutter with features like a fixed rod, pressing plate, and graduated scales for improved paper alignment and safety, and an improved paper cutting machine with a moveable positioning block and pedal for efficient cutting of papers of different widths. While these contexts provide insights into innovative paper cutting tools, they do not directly relate to a specific paper by Cutter, Burton, and Emrich in 2003.Dose of Gemcitabine for colorectal cancer treatment

In the treatment of colorectal cancer, gemcitabine has shown efficacy in certain scenarios. Research suggests that gemcitabine can be a valuable option for patients with oxaliplatin-resistant colorectal cancer, as it induces apoptosis by inhibiting the Akt and p38 MAPK pathways, leading to cell death. Additionally, a study on metastatic colorectal cancer patients who had progressed through various regimens found that gemcitabine in combination with capecitabine was tolerable and associated with clinical benefit, showing objective response rates and stable disease rates, with a median progression-free survival of 2.87 months and overall survival of 6.53 months. Therefore, gemcitabine, either alone or in combination, can be considered as a treatment option for colorectal cancer patients, especially in cases of resistance to other chemotherapy agents.What is Chemotherapy Drugs?

Chemotherapy drugs are cytotoxic agents used to treat various types of cancer. They work by targeting rapidly dividing cancer cells, disrupting their growth and division. These drugs can be administered intravenously, orally, or through injections. Common chemotherapy drug categories include anthracycline antibiotics, antimetabolites, alkylating agents, and plant alkaloids. While chemotherapy can have side effects like nausea, vomiting, hair loss, and fatigue, it can also cause inflammation and damage to organs like the heart, lungs, liver, and nerves. Advances in oncology have led to the development of more effective agents with reduced adverse effects, improving cancer treatment outcomes. Examples of chemotherapy drugs include cisplatin, carboplatin, paclitaxel, and fluorouracil.What is the future direction of brentuximab?

The future direction of brentuximab vedotin involves its potential in treating various cancers beyond Hodgkin lymphoma. Studies have shown its efficacy in targeting CD30 positive tumor cells, leading to promising outcomes in Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin has been approved for frontline treatment of advanced-stage Hodgkin lymphoma patients and as maintenance therapy post-transplant, indicating its expanding role in different treatment settings. Additionally, research suggests that brentuximab vedotin could be beneficial in other CD30 positive B cell lymphomas, systemic T cell lymphomas, and mycosis fungoides, showcasing its potential in a broader spectrum of malignancies. The ongoing clinical trials exploring brentuximab vedotin's effectiveness in various cancers may lead to significant advancements in treatment strategies for these diseases.How aml is treated?

AML is treated through various approaches. Traditional cytotoxic regimens are initially employed, followed by targeted therapies like FLT3 inhibitors and IDH inhibitors, which have shown efficacy in specific patient populations. Achieving complete remission (CR) is crucial, with consolidation treatment options including chemotherapy or allogeneic hematopoietic cell transplant (HCT) to improve long-term survival. Novel therapies under investigation for AML include antibody therapies targeting CD47 and TIM-3, bispecific antibodies, and CAR-T-cell therapies, aiming to enhance treatment outcomes. Personalized treatment based on genomic signatures is gaining importance, with a focus on targeting specific pathways involved in AML cell survival, drug resistance, and immune evasion to improve overall treatment responses. Further exploration of combination therapies targeting multiple pathways is warranted for broader patient benefit.How was digoxin in the treatment of anthracycline resistant breast cancer?

Digoxin has shown promising effects in the treatment of anthracycline-resistant breast cancer. Studies have indicated that digoxin can reverse resistance in breast cancer cells by down-regulating HIF-1α and MDR1 expression, reducing the resistance index significantly. Additionally, digoxin has demonstrated anti-tumor activity in breast cancer cells by inhibiting cell growth, increasing apoptosis, and altering the Bax/Bcl-2 ratio, leading to mitochondria-dependent apoptosis. Anthracycline resistance in breast cancer poses a challenge, but digoxin's ability to overcome this resistance by affecting key pathways and promoting apoptosis showcases its potential as a valuable therapeutic option in anthracycline-resistant cases.What are the implications of BRCA1 mutation on the efficacy of personalized therapeutic interventions for breast cancer?

BRCA1 mutations play a significant role in the efficacy of personalized therapeutic interventions for breast cancer. Mutations in BRCA1 lead to DNA repair defects, making tumors more vulnerable to therapies like Poly (ADP-ribose) polymerase inhibitors (PARPi). These mutations result in homologous recombination repair deficiencies, affecting responses to platinum salt therapies and PARP inhibitors. However, the efficacy of these treatments can be impacted by the development of resistance due to interconnected DNA repair pathways compensating for each other. Additionally, BRCA1 promoter methylation can lead to poor outcomes and adaptive chemoresistance, altering therapeutic responses in TNBC and ovarian cancers. Understanding the implications of BRCA1 mutations is crucial for tailoring effective treatment strategies in breast cancer patients.Is there any case report of tp53 (R248Q) mutation associated with adrenocortical carcinoma?

Yes, there are reported cases of TP53 mutations associated with adrenocortical carcinoma (ACC). Specifically, a case study identified a TP53-G245C mutation in the germline, primary ACC, and xenograft tumor. Additionally, another case study highlighted a 77-year-old man with ACC harboring TP53 mutations in both sarcomatoid and non-sarcomatoid components, which may have influenced the tumor's evolution. Furthermore, a case report discussed a 4-year-old female patient with ACC presenting with various symptoms, including a left supra-renal mass invading the inferior vena cava, emphasizing the aggressive nature of ACC and the importance of early detection. These cases underscore the significance of TP53 mutations in the pathogenesis and clinical manifestations of adrenocortical carcinoma.What are the potential mechanisms underlying the association between ICIP and TMB, and how might these influence treatment decisions?

The association between immune checkpoint inhibitor therapy (ICI) and tumor mutational burden (TMB) involves several key mechanisms. High TMB has been linked to improved survival with ICI treatment, but not all high-TMB patients respond well. Specific gene alterations impact outcomes differently in TMB-high and TMB-low patients, influencing response to ICI. For instance, mutations in genes like STK11 and E2F3 are associated with worse outcomes in TMB-high tumors, while mutations in genes like NTRK and PTPRD are linked to better outcomes. Additionally, the immune-excluded phenotype, characterized by high stromal TIL and low intratumoral TIL density, is correlated with high TGFBs and poor response to immunotherapy. These insights can guide treatment decisions by helping identify patients likely to benefit from ICI based on their TMB status and specific gene alterations.Cancer and target therapy

Targeted therapy for cancer is a personalized approach that aims to specifically target cancer cells while minimizing damage to healthy cells by focusing on molecular or genetic changes unique to cancer cells. This method has shifted oncology towards individualized treatment based on deep molecular analysis, allowing for tailored therapies guided by the tumor's specific molecular alterations. While traditional treatments like surgery and chemotherapy have limitations such as adverse effects and metastasis, targeted therapy offers a promising alternative by blocking the growth and spread of cancer cells through specific molecule targeting. The foundation of precision medicine, targeted therapy targets proteins controlling cancer cell growth, with advancements like stimuli-responsive drug delivery systems enhancing treatment efficacy. Despite challenges like drug resistance, targeted therapy presents significant therapeutic advantages and development prospects in cancer treatment.Cancer cell membrane borospherene for targeted delivery

Cancer cell membrane-coated boron nitride nanomaterials have shown great potential for targeted drug delivery in cancer therapy. These biomimetic nanoplatforms combine the advantages of boron nitride nanoparticles (BN) with the targeting ability of cancer cell membranes (CCM). By encapsulating BNs with cancer cell membranes, these nanoplatforms exhibit enhanced dispersibility, cytocompatibility, and homologous targeting of cancer cells, leading to increased cellular uptake and improved cytotoxicity against cancer cells. Furthermore, the incorporation of cancer cell membrane onto BN nanospheres has shown to enhance tumor-selective drug delivery, resulting in efficient tumor inhibition. This innovative approach holds promise for personalized and targeted cancer therapy, offering a potential solution to the challenges of drug delivery in cancer treatment.